首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷手術用器具電子醫療設備核子醫學

市場調查報告書

商品編碼

1419134

影像導引放射治療市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按類型、應用、成像類型、最終用戶和地理位置

Image Guided Radiotherapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Application, Imaging Type, End Users, and Geography

出版日期: 2023年11月12日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

依據「2030 年影像導引放射治療市場預測 - 全球分析 - 按類型、應用、成像類型和最終用戶」的最新研究報告，2022 年市場估值為 18.14 億美元，預計將達到2030年將達到56.5億；預計2022-2030年CAGR為15.3%。

該市場的成長歸因於全球癌症盛行率的上升以及技術先進系統的引入。此外，癌症篩檢計劃和標準指南的實施預計將為市場成長提供成長機會。然而，影像導引放射治療的高成本將阻礙市場成長。

全球衛生系統的癌症盛行率正在大幅增加。根據世界衛生組織 (WHO) 的數據，2019 年全球約有 960 萬人死於癌症。根據同一來源，大腸直腸癌、肝癌、前列腺癌、肺癌和胃癌在男性中最常見，而乳癌、大腸癌和子宮頸癌在女性中最常見。

據英國癌症研究中心稱，2020年，英國每年約有16萬人死於癌症。據世界衛生組織稱，癌症是全球死亡的主要原因之一，到 2020 年將導致約 1,000 萬人死亡。 2020 年最常見的癌症是乳癌（226 萬例）和肺癌（221 萬例）。根據美國癌症協會預測，到 2040 年，全球癌症負擔預計將達到約 2,840 萬例，較 2020 年增加 47%，其中由於人口變化，發展中國家的增加幅度更大。然而，全球化和經濟成長可能加劇風險因素的增加，從而進一步加劇這種情況。全球癌症觀察站（GLOBOCAN）估計，2020年全球有1930萬癌症病例。GLOBOCAN預測，2040年印度癌症病例將比2020年上升至208萬，成長57.5%。據世界衛生組織稱，全球有近230 萬名女性被檢測出患有乳腺癌，2020 年約有685,000 人因此死亡。據Advocate Health Care 稱，超過60% 的癌症患者接受某種形式的放射治療，作為其治療的一部分。治療。這是因為放射療法在對抗多種類型的癌症方面非常有效，因為它會破壞癌細胞的繁殖能力。影像導引放射治療使放射治療師能夠更好地定位目標區域，並在治療前甚至治療期間將放射束引導至腫瘤。因此，癌症的高盛行率預計將推動影像導引放射治療的採用。

根據世界衛生組織 2021 年 3 月發布的資料，超過 50% 的癌症患者將放射治療作為癌症管理和護理的一部分。此外，根據相同的資料，放射療法主要用於治療最常見的癌症類型，例如大腸癌、肺癌、乳癌和子宮頸癌。從患者的角度來看，早期發現和診斷可以避免不必要的痛苦和痛苦。它還可以減少治療規模和成本。此外，政府意識將推動市場。例如，英國公共衛生部與英國衛生部和英國國民醫療服務體系 (NHS England) 合作，領導了「明確癌症」計畫。該計劃旨在透過提高公眾對癌症跡象和症狀的認知來改善癌症的早期診斷，並進一步敦促人們立即去看醫生。

技術先進系統的引入推動了影像導引放射治療市場的成長

成像是診斷過程的基本部分。從超音波到 MRI 和 CT 掃描，放射科醫生利用醫學影像來正確診斷和治療疾病。此外，醫生還使用影像技術來確定特定療法是否有效治療了患者。在過去的幾十年裡，成像能力急劇增強。成像技術取得了許多進步。這項進展對於提供準確的診斷和改善患者護理非常重要。這些進步以及人工智慧和數位技術的力量提高了提供和完成患者護理的程序效率。人工智慧（AI）有助於改善醫療保健產業的各個方面，醫學影像技術是受益最大的領域之一。人工智慧正在應用於先進的成像設備，可以幫助更早發現疾病，並在診斷和早期治療過程中進行指導。

2021年8月，印度第二大多專科醫院Manipal Hospitals推出了先進的Radixact系統，配備Synchrony Automatic即時運動同步技術，用於精確治療癌症患者。飛利浦於 2023 年透過 Zenition 10 擴展了公司的行動 C 臂產品組合。2023 年，GE Healthcare 透過 AIR 技術擴展了 PET/MR 功能，以提高診斷精度、治療評估和患者舒適度。 2023 年，Pixxoscan 的推出擴大了 GE Healthcare 的 MRI 造影劑產品組合。 2022 年 2 月，印度 Saket Max 癌症護理研究所 (MICC) 的放射腫瘤科推出了 Radixact X9 Tomotherapy，結合第二代同步呼吸運動管理系統。這種針對癌症患者的放射治療採用基於人工智慧（AI）的即時追蹤和治療實施方式，確保放射治療過程中不會因胸部或腹部呼吸運動而錯過腫瘤。 2021年9月，SkinCure Oncology宣布了積極的臨床試驗結果，展示了影像導引表淺放射治療（IGSRT）治療基底細胞癌（BCC）和鱗狀細胞癌（SCC）的積極資料（治癒率99.3%）。因此，此類技術進步預計將推動影像導引放射治療市場的成長。

基於類型的見解

影像導引放射治療市場依類型分為產品和服務。產品領域在 2022 年佔據最大的市場佔有率。服務領域預計在 2022 年至 2030 年期間CAGR最高，達到 15.5%。人們對放射治療的認知不斷提高，從而增加了對直線加速器 (LINAC) 和 MRI-LINAC 等放射治療設備的需求，這些設備有助於為大量患者提供治療。此外，腫瘤中心的巨大成長，進一步產生了對放射治療設備的需求，推動了產品領域並促進了影像導引放射治療市場的成長。

基於應用程式的見解

根據應用，影像導引放射治療市場分為乳癌、肺癌、胃腸癌、攝護腺癌、婦科癌症、頭頸癌等。乳癌細分市場在 2022 年佔據最大的市場佔有率。預計肺癌細分市場在 2022 年至 2030 年期間CAGR最高，達到 16.3%。

基於成像類型的見解

根據影像學類型，影像導引放射治療市場分為磁振造影（MRI）、正子斷層掃描（PET）、電腦斷層掃描（CT）影像等。磁振造影 (MRI) 領域在 2022 年佔據最大的市場佔有率。電腦斷層掃描 (CT) 成像領域預計 2022 年至 2030 年CAGR最高，達到 15.8%。

基於最終用戶的見解

根據最終用戶，影像導引放射治療市場分為醫院、腫瘤中心和放射治療中心。醫院細分市場在 2022 年佔據最大的市場佔有率。腫瘤中心細分市場預計在 2022 年至 2030 年期間的CAGR最高，為 16.0%。

領先企業正在實施擴大市場佔有率和多元化、推出新產品以及獲取新客戶群等策略，以挖掘現有的商機。

2023 年 5 月，飛利浦透過 Zenition 10 擴展了其行動 C 臂產品組合。

2023 年 4 月，GE HealthCare 推出 Pixxoscan，擴大了其磁振造影 (MRI) 造影劑產品組合。它為客戶提供了兩種領先的大環分子：Clariscan（钆特酸）和 Pixxoscan（钆布醇）。

2023 年 6 月，GE HealthCare 宣布計劃利用 AIR 技術擴展其 PET/MR 功能，以提高診斷精度並簡化治療評估，同時提高患者舒適度。

2022年9月，中國監管機構國家藥品監督管理局（NMPA）批准了ViewRay的MRIdian磁振造影導引放射治療系統的銷售和使用。

2022年3月，全南大學和順醫院引進「Halcyon 3.0」放射治療系統並用於綜合治療。 Halcyon 3.0 是一種最先進的放射癌症治療設備，可提供基於即時影像導引的強度調節放射治療。

美國食品藥物管理局、疾病管制與預防中心 (CDC) 和全球疾病負擔研究是準備影像導引放射治療市場報告時參考的主要和次要來源。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 12 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第13章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 14 章：影像導引放射治療市場 - 主要公司概況

ViewRay

注意 - 將為以下公司列表提供類似資訊

通用電氣醫療集團
日立製作所
西門子公司
皇家飛利浦公司
東芝公司
瓦里安醫療系統公司
視覺RT有限公司
醫科達公司
安科瑞公司
堀場集團

第 15 章：附錄

詞彙表
關於 Insight Partners
市場情報雲

簡介目錄

Product Code: TIPRE00009118

According to our new research study on "Image Guided Radiotherapy Market Forecast to 2030 - Global Analysis - by Type, Application, Imaging Type, and End User," the market was valued at US$ 1.814 billion in 2022 and is projected to reach US$ 5.650 billion by 2030; it is estimated to register a CAGR of 15.3% during 2022-2030.

The market's growth is due to the rising prevalence of cancer worldwide and the introduction of technologically advanced systems. Further, cancer screening programs and the implementation of standard guidelines are expected to provide growth opportunities for the market growth. However, the high cost of image-guided radiotherapy treatment will hinder market growth.

Health systems across the globe are witnessing a substantial increase in the prevalence of cancer. According to the World Health Organization (WHO), in 2019, ~9.6 million deaths were due to cancer across the globe. According to the same source, colorectal, liver, prostate, lung, and stomach cancer are most observed in men, while breast, colorectal, and cervical cancer are the most common among women.

According to Cancer Research UK, in 2020, ~0.16 million people in the UK die each year due to cancer. Cancer is one of the leading reasons of death globally, causing ~10 million deaths in 2020, according to the WHO. The most common forms of cancer in 2020 were breast cancer (2.26 million cases) and lung cancer (2.21 million cases). According to the American Cancer Society, the burden of cancer worldwide is expected to reach ~28.4 million cases by 2040, increased by 47% from 2020, with greater increases in developing countries due to demographic changes. However, this is further compounded by increasing risk factors that can be exacerbated by globalization and a growing economy. The Global Cancer Observatory (GLOBOCAN) estimates that there were 19.3 million cases of cancer worldwide in 2020. GLOBOCAN predicted that cancer cases in India would rise to 2.08 million in 2040 compared to 2020, an increase of 57.5%. According to WHO, nearly 2.3 million women worldwide were detected with breast cancer, and ~685,000 deaths were registered due to the same in 2020. According to Advocate Health Care, over 60% of cancer patients undergo some form of radiation therapy as part of their treatment. This is because radiation therapy is very effective in fighting several types of cancer as it destroys the cancer cell's ability to reproduce. Image-guided radiotherapy allows the radiation therapist to locate the target area better and direct the beam of radiation at the tumor immediately before or even during treatment. Thus, the high prevalence of cancer is anticipated to drive the adoption of image-guided radiotherapy.

According to data published by the WHO in March 2021, over 50% of cancer patients involve radiotherapy as part of cancer management and care. Moreover, according to the same data, radiotherapy is prominently used to treat the most common types of cancer, such as colorectal, lung, breast, and cervical cancer. From the patient's point of view, early detection and diagnosis can prevent unnecessary pain and suffering. It can also reduce the scale and cost of treatment. Further, government awareness will propel the market. For instance, Public Health England, in partnership with the Department of Health and NHS England, leads the "Be Clear on Cancer" program. The program aims to improve early diagnosis of cancer by increasing public awareness of the signs and symptoms of cancer and further urging people to see their doctors without delay.

Introduction of Technologically Advanced Systems Fuels Image-Guided Radiotherapy Market Growth

Imaging is a fundamental part of the diagnostic process. From ultrasounds to MRIs and CT scans, radiologists use medical imaging to diagnose and treat diseases properly. Also, doctors use imaging technologies to determine whether a particular therapy has effectively treated a patient. Over the past couple of decades, the capabilities of imaging have radically increased. Numerous advancements in imaging technologies have occurred. This progress is important in providing accurate diagnoses and bettering patient care. These advancements and the power of AI and digital technology raise better procedural efficiency in providing and accomplishing patient care. Artificial intelligence (AI) helps improve various parts of the healthcare industry, medical imaging technology being one of the fields benefiting greatly. AI is being used in advanced imaging devices, which can help detect diseases earlier and guide them during diagnosis and early treatment.

In August 2021, Manipal Hospitals, India's second largest multi-specialty hospital, launched an advanced Radixact system equipped with Synchrony Automatic, real-time motion synchronization technology for precisely treating cancer patients. Philips expanded the company's mobile C-arm portfolio through Zenition 10 in 2023. In 2023, GE Healthcare expanded PET/MR capabilities with AIR technologies to improve diagnostic precision, treatment evaluation, and patient comfort. In 2023, the launch of Pixxoscan expanded GE Healthcare's MRI contrast agent portfolio. In February 2022, the Department of Radiation Oncology at Max Institute of Cancer Care (MICC), Saket, India, launched Radixact X9 Tomotherapy, combined with the 2nd Generation Synchronized Respiratory Motion Management System. This radiation therapy treatment for cancer patients uses artificial intelligence (AI)-based real-time tracking and treatment delivery to ensure that the tumor is not missed due to chest or abdominal breathing movement during radiation treatment. In September 2021, SkinCure Oncology announced positive clinical trial results, demonstrating positive data (99.3% cure rate) for image-guided superficial radiotherapy (IGSRT) in the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Therefore, such technological advancements are expected to drive the growth of the image-guided radiotherapy market.

Type-Based Insights

The image-guided radiotherapy market is segmented into product and services based on type. The product segment held the largest market share in 2022. The services segment is anticipated to register the highest CAGR of 15.5% during 2022-2030. Increasing awareness about radiation therapy has increased the demand for radiotherapy equipment such as linear accelerators (LINAC) and MRI-LINAC, which help deliver the therapy to large patient populations. Moreover, there has been tremendous growth in oncology centers, further generating the demand for radiotherapy equipment, driving the product segment and contributing to the image-guided radiotherapy market growth.

Application-Based Insights

Based on application, the image-guided radiotherapy market is segmented into breast cancer, lung cancer, gastrointestinal cancer, prostate cancer, gynecological cancers, head and neck cancer, and others. The breast cancer segment held the largest market share in 2022. The lung cancer segment is anticipated to register the highest CAGR of 16.3% during 2022-2030.

Imaging Type -Based Insights

Based on imaging type, the image-guided radiotherapy market is segmented into magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT) imaging, and others. The magnetic resonance imaging (MRI) segment held the largest market share in 2022. The computed tomography (CT) imaging segment is anticipated to register the highest CAGR of 15.8% from 2022 to 2030.

End User-Based Insights

Based on the end user, the image-guided radiotherapy market is segmented into hospitals, oncology centers, and radiotherapy centers. The hospitals segment held the largest market share in 2022. The oncology centers segment is anticipated to register the highest CAGR of 16.0% during 2022-2030.

Leading players are implementing strategies such as expanding and diversifying their market presence, launching new products, and acquiring a new customer base to tap prevailing business opportunities.

In May 2023, Philips expanded its mobile C-arm portfolio with Zenition 10.

In April 2023, GE HealthCare expanded its portfolio of magnetic resonance imaging (MRI) contrast agents with the launch of Pixxoscan. It provides customers access to two leading macrocyclic molecules: Clariscan (gadoteric acid) and Pixxoscan (gadobutrol).

In June 2023, GE HealthCare announced its plans to expand its PET/MR capabilities with AIR technologies to improve diagnostic precision and simplify treatment evaluation while increasing patient comfort.

In September 2022, the National Medical Products Administration (NMPA), China's regulatory authority, approved the sale and use of ViewRay's MRIdian MRI-guided radiation therapy system.

In March 2022, Hwasun Hospital of Chonnam National University introduced the "Halcyon 3.0" radiotherapy system and used it for comprehensive treatment. Halcyon 3.0 is a state-of-the-art radiation cancer treatment device that can deliver intensity-modulated radiation therapy based on real-time image guidance.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are the primary and secondary sources referred to while preparing the image-guided radiotherapy market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Image Guided Radiotherapy Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Image Guided Radiotherapy Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Image Guided Radiotherapy Market - Global Market Analysis

6.1 Image Guided Radiotherapy - Global Market Overview
6.2 Image Guided Radiotherapy - Global Market and Forecast to 2030

7. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Product
7.3 Services

8. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By Application, 2020-2030

8.1 Overview
8.2 Breast Cancer
8.3 Lung Cancer
8.4 Prostate Cancer
8.5 Gastrointestinal Cancer
8.6 Gynecological Cancer
8.7 Head and Neck Cancer
8.8 Others

9. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By Imaging Type, 2020-2030

9.1 Overview
9.2 Computed Tomography (CT)
9.3 Magnetic Resonance Imaging (MRI)
9.4 Positron Emission Tomography (PET)
9.5 Others

10. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

10.1 Overview
10.2 Hospitals
10.3 Oncology Centers
10.4 Radiotherapy Centers

11. Image Guided Radiotherapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

11.1 North America
- 11.1.1 North America Image Guided Radiotherapy Market Overview
- 11.1.2 North America Image Guided Radiotherapy Market Revenue and Forecasts to 2030
- 11.1.3 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Type
- 11.1.4 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Application
- 11.1.5 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Imaging Type
- 11.1.6 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By End User
- 11.1.7 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Image Guided Radiotherapy Market
    - 11.1.7.1.1 United States Image Guided Radiotherapy Market, by Type
    - 11.1.7.1.2 United States Image Guided Radiotherapy Market, by Application
    - 11.1.7.1.3 United States Image Guided Radiotherapy Market, by Imaging Type
    - 11.1.7.1.4 United States Image Guided Radiotherapy Market, by End User
  - 11.1.7.2 Canada Image Guided Radiotherapy Market
    - 11.1.7.2.1 Canada Image Guided Radiotherapy Market, by Type
    - 11.1.7.2.2 Canada Image Guided Radiotherapy Market, by Application
    - 11.1.7.2.3 Canada Image Guided Radiotherapy Market, by Imaging Type
    - 11.1.7.2.4 Canada Image Guided Radiotherapy Market, by End User
  - 11.1.7.3 Mexico Image Guided Radiotherapy Market
    - 11.1.7.3.1 Mexico Image Guided Radiotherapy Market, by Type
    - 11.1.7.3.2 Mexico Image Guided Radiotherapy Market, by Application
    - 11.1.7.3.3 Mexico Image Guided Radiotherapy Market, by Imaging Type
    - 11.1.7.3.4 Mexico Image Guided Radiotherapy Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe
- 11.2.1 Germany
- 11.2.2 France
- 11.2.3 Italy
- 11.2.4 Spain
- 11.2.5 United Kingdom
- 11.2.6 Rest of Europe
11.3 Asia-Pacific
- 11.3.1 Australia
- 11.3.2 China
- 11.3.3 India
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
- 11.4.1 South Africa
- 11.4.2 Saudi Arabia
- 11.4.3 U.A.E
- 11.4.4 Rest of Middle East and Africa
11.5 South and Central America
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Rest of South and Central America

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. Image Guided Radiotherapy Market - Key Company Profiles

14.1 ViewRay
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies